TABLE 4

Multivariate analysis of the association of patient factors with efavirenz pharmacokinetic parameters in HIV-infected children with and without tuberculosis

PK parameter^a	Predictor	Estimate	SE	Standardized estimate	P value
C_max	Age (yrs)	−0.052	0.017	−0.346	0.004
	Dose (mg)	0.003	0.001	0.518	<0.001
	CYP2B6 516TT	0.576	0.080	0.544	<0.001
C_12h	Age (yrs)	−0.048	0.019	−0.279	0.014
	Dose (mg)	0.003	0.001	0.366	0.001
	CYP2B6 516TT	0.774	0.088	0.637	<0.001
C_min	Age (yrs)	−0.034	0.021	−0.177	0.121
	Dose (mg)	0.002	0.001	0.280	0.015
	CYP2B6 516TT	0.873	0.098	0.652	<0.001
AUC_0–24h	Age (yrs)	−0.059	0.024	−0.274	0.016
	Dose (mg)	0.004	0.001	0.403	<0.001
	CYP2B6 516TT	0.957	0.109	0.630	<0.001
CL/F	Age (yrs)	0.042	0.012	0.260	<0.001
CL/F	CYP2B6 516TT	−0.739	0.083	−0.640	<0.001

↵a C_max, peak concentration; C_12h, concentration at 12 h postdose; C_min, minimum concentration; AUC_0–24h, total area under the curve from time 0 to 24 h; CL/F, apparent oral clearance. TB coinfection status, sex, weight, and height were not associated with efavirenz pharmacokinetic parameters in the multivariate model.